Welcome to our dedicated page for Lexaria Bioscience Warrant news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience Warrant stock.
Lexaria Bioscience Corp. (NASDAQ:LEXXW) is a global innovator in drug delivery platforms known for its patented drug delivery technology, DehydraTECH. DehydraTECH enhances the absorption of active pharmaceutical ingredients, such as cannabinoids and nicotine, by promoting more effective oral delivery. The technology has shown to significantly increase bio-absorption, reduce onset times, and mask unwanted tastes. Lexaria operates in four main segments: Intellectual Property Licensing, B2B Production, Research and Development, and Corporate. With a robust intellectual property portfolio and ongoing research, Lexaria aims to revolutionize drug delivery methods and improve outcomes.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced a media and digital marketing agreement with SRAX to enhance investor engagement over the next year. This follows substantial progress made by the company in 2021, with plans for an extensive 2022 including a human hypertension study and a nicotine study. Lexaria will issue 224,299 restricted shares valued at $1.2 million to SRAX for its services. The agreement aims to maximize visibility through a sustained marketing campaign, leveraging SRAX's analytical capabilities.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announces the near completion of its human clinical study HYPER-H21-3, which is exploring the effects of DehydraTECH-CBD on acute pulmonary hypertension. The study involved a placebo-controlled trial with 16 volunteers receiving a 300mg dose of DehydraTECH-CBD. Blood samples are currently being analyzed, with results expected soon. This research aims to contribute to the understanding of DehydraTECH-CBD as a treatment for hypertension and will be submitted to the FDA as part of their investigational drug research program.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has released follow-up results from clinical study HYPER-H21-2, indicating that its DehydraTECH-CBD significantly reduces arterial stiffness after just one day of dosing. This finding suggests potential applications beyond hypertension, including in cardiovascular health. Notably, pulse wave velocity (PWV) was measured at 8.1 ± 0.3 m/s for DehydraTECH-CBD versus 8.3 ± 0.3 m/s for placebo, with all comparisons yielding statistically significant results (p < 0.01). Future studies, including the upcoming HYPER-H21-4, will explore these findings further.
Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) announces ambitious R&D plans for 2022, focusing on its DehydraTECH platform. Key studies include an investigation into heart disease and hypertension, as well as oral nicotine delivery alternatives. With funding of approximately USD$15 million secured, Lexaria aims to enhance drug delivery for treatments including dementia, rheumatoid disease, and diabetes. The company is debt-free and expects its cash reserves to sustain operations until at least Q2 2023. Strategic partnerships are planned post-data generation.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has announced a new hypertension study, HYPER-H21-4, aimed at evaluating its DehydraTECH-CBD. This ambitious study involves 60 participants aged 45-70 and aims to gather data over six weeks, assessing various health metrics. Positive results could aid regulatory approval for DehydraTECH-CBD as a hypertension treatment. Additionally, updates on three ongoing studies show promising potential in blood pressure reduction. The global hypertension market represents a significant opportunity, valued at $28 billion annually.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has launched a study (EPIL-A21-1) to assess the effectiveness of its DehydraTECHTM-CBD against the FDA-approved Epidiolex in reducing seizure activity. This animal study involves a leading US lab and is expected to yield results by Q3 2022. In addition, Lexaria has secured its first patent for DehydraTECH in Mexico and a fifth patent in Japan for its use with cannabinoids. Lexaria continues to expand its intellectual property portfolio, with a total of 23 patents granted worldwide.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced significant findings from its study THC-A21-1, demonstrating that its DehydraTECH technology delivers oral THC into the bloodstream three times faster than standard methods, achieving comparable plasma levels within just 15 minutes versus 45 minutes. The study highlighted that the DehydraTECH-THC formulation produced statistically significant improvements in both peak THC delivery and total absorption over time. This technology aims to meet the needs of modern THC users seeking effective pain management solutions without harmful delivery methods.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced promising results from its oral nicotine absorption study NIC-A21-1, showcasing its DehydraTECH technology. The study indicated that DehydraTECH-nicotine reached blood plasma levels 10 to 20 times faster than control methods, achieving peak levels up to 10 times higher. The technology was designed to improve nicotine delivery via oral pouches, aiming to provide a safer alternative for smokers. A larger human study is planned to further validate results against leading brands in the growing nicotine oral pouch market, projected to reach $21.8 billion by 2027.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) will be featured at the 23rd Annual H.C. Wainwright Global Investment Conference from September 13-15, 2021. CEO Chris Bunka will share the latest company updates starting September 13 at 7:00 AM ET. Attendees can register on the conference website. Lexaria's patented DehydraTECH technology enhances drug absorption and is also evaluated for various pharmaceutical applications. The company holds 21 patents and 50 pending worldwide, demonstrating strong intellectual property.
Lexaria Bioscience Corp. has initiated the process for an Investigational New Drug (IND) application with the FDA for its DehydraTECH-CBD formulation aimed at treating hypertension. This decision follows successful results from multiple studies demonstrating the formulation's bioabsorption and effectiveness in reducing blood pressure without significant side effects. Lexaria is working with a consultancy for regulatory compliance and plans to leverage upcoming clinical studies to bolster its application. The hypertension market is valued at approximately $28 billion and presents significant growth potential.
FAQ
What is the current stock price of Lexaria Bioscience Warrant (LEXXW)?
What is Lexaria Bioscience Corp. known for?
In which segments does Lexaria operate?
What are the key benefits of DehydraTECH?
What is the main goal of Lexaria Bioscience Corp.?
How does DehydraTECH impact drug delivery across the blood-brain barrier?
What is the significance of Lexaria's intellectual property portfolio?
Who owns and manufactures GLP-1 drugs like Rybelsus and Ozempic?
What is the focus of Lexaria's ongoing research?
How does Lexaria plan to enhance the delivery of tirzepatide in its latest Study?
What sets Lexaria Bioscience Corp. apart from other innovators in drug delivery platforms?
